- Associated Press - Wednesday, December 19, 2012

BERLIN (AP) - German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.

The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.

Merck shares fell 3.1 percent to (EURO)98.20 ($129.41) after the announcement early Wednesday.

The company is a separate entity from Merck & Co., which is based in the U.S.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide